FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006884773> ?p ?o ?g. }

• W3006884773 endingPage "1884" @default.
• W3006884773 startingPage "1875" @default.
• W3006884773 abstract "Recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are genetic hallmarks of angioimmunoblastic T-cell lymphoma (AITL). Mice expressing the p.Gly17Val RHOA mutant on a Tet2-null background succumbed to AITL-like T-cell lymphomas due to deregulated T-cell receptor (TCR) signaling. Using these mice to investigate therapeutics for AITL, we found that dasatinib, a multikinase inhibitor prolonged their survival through inhibition of hyperactivated TCR signaling. A phase I clinical trial study of dasatinib monotherapy in 5 patients with relapsed/refractory AITL was performed. Dasatinib was started at a dose of 100 mg/body once a day and continued until days 10-78 (median day 58). All the evaluable patients achieved partial responses. Our findings suggest that AITL is highly dependent on TCR signaling and that dasatinib could be a promising candidate drug for AITL treatment. SIGNIFICANCE: Deregulated T-cell receptor signaling is a critical molecular event in angioimmunoblastic T-cell lymphoma and can be targeted with dasatinib." @default.
• W3006884773 created "2020-03-06" @default.
• W3006884773 creator A5000831209 @default.
• W3006884773 creator A5001399725 @default.
• W3006884773 creator A5010836878 @default.
• W3006884773 creator A5013212494 @default.
• W3006884773 creator A5014246737 @default.
• W3006884773 creator A5014405945 @default.
• W3006884773 creator A5015530478 @default.
• W3006884773 creator A5033502470 @default.
• W3006884773 creator A5038248329 @default.
• W3006884773 creator A5042588749 @default.
• W3006884773 creator A5048163457 @default.
• W3006884773 creator A5050383391 @default.
• W3006884773 creator A5056504247 @default.
• W3006884773 creator A5066055908 @default.
• W3006884773 creator A5067804516 @default.
• W3006884773 creator A5068565363 @default.
• W3006884773 creator A5068950132 @default.
• W3006884773 creator A5070909554 @default.
• W3006884773 creator A5073561843 @default.
• W3006884773 creator A5082957036 @default.
• W3006884773 creator A5083708498 @default.
• W3006884773 creator A5089203135 @default.
• W3006884773 creator A5090225262 @default.
• W3006884773 date "2020-05-01" @default.
• W3006884773 modified "2023-10-14" @default.
• W3006884773 title "Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma" @default.
• W3006884773 cites W1516775823 @default.
• W3006884773 cites W1988586881 @default.
• W3006884773 cites W2003973314 @default.
• W3006884773 cites W2028078153 @default.
• W3006884773 cites W2029254213 @default.
• W3006884773 cites W2034851497 @default.
• W3006884773 cites W2038970416 @default.
• W3006884773 cites W2067191435 @default.
• W3006884773 cites W2069271377 @default.
• W3006884773 cites W2069426612 @default.
• W3006884773 cites W2074678620 @default.
• W3006884773 cites W2097799776 @default.
• W3006884773 cites W2107724577 @default.
• W3006884773 cites W2113687173 @default.
• W3006884773 cites W2121960517 @default.
• W3006884773 cites W2130410032 @default.
• W3006884773 cites W2133201432 @default.
• W3006884773 cites W2146146853 @default.
• W3006884773 cites W2148495628 @default.
• W3006884773 cites W2169331771 @default.
• W3006884773 cites W2416844197 @default.
• W3006884773 cites W2573926257 @default.
• W3006884773 cites W2624092568 @default.
• W3006884773 cites W2728024715 @default.
• W3006884773 cites W2779133245 @default.
• W3006884773 cites W2786374981 @default.
• W3006884773 cites W2787325046 @default.
• W3006884773 cites W2789940425 @default.
• W3006884773 cites W2795353272 @default.
• W3006884773 cites W2802766600 @default.
• W3006884773 cites W2804469756 @default.
• W3006884773 cites W2896907494 @default.
• W3006884773 cites W2904205732 @default.
• W3006884773 cites W4233431843 @default.
• W3006884773 doi "https://doi.org/10.1158/0008-5472.can-19-2787" @default.
• W3006884773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32107212" @default.
• W3006884773 hasPublicationYear "2020" @default.
• W3006884773 type Work @default.
• W3006884773 sameAs 3006884773 @default.
• W3006884773 citedByCount "35" @default.
• W3006884773 countsByYear W30068847732020 @default.
• W3006884773 countsByYear W30068847732021 @default.
• W3006884773 countsByYear W30068847732022 @default.
• W3006884773 countsByYear W30068847732023 @default.
• W3006884773 crossrefType "journal-article" @default.
• W3006884773 hasAuthorship W3006884773A5000831209 @default.
• W3006884773 hasAuthorship W3006884773A5001399725 @default.
• W3006884773 hasAuthorship W3006884773A5010836878 @default.
• W3006884773 hasAuthorship W3006884773A5013212494 @default.
• W3006884773 hasAuthorship W3006884773A5014246737 @default.
• W3006884773 hasAuthorship W3006884773A5014405945 @default.
• W3006884773 hasAuthorship W3006884773A5015530478 @default.
• W3006884773 hasAuthorship W3006884773A5033502470 @default.
• W3006884773 hasAuthorship W3006884773A5038248329 @default.
• W3006884773 hasAuthorship W3006884773A5042588749 @default.
• W3006884773 hasAuthorship W3006884773A5048163457 @default.
• W3006884773 hasAuthorship W3006884773A5050383391 @default.
• W3006884773 hasAuthorship W3006884773A5056504247 @default.
• W3006884773 hasAuthorship W3006884773A5066055908 @default.
• W3006884773 hasAuthorship W3006884773A5067804516 @default.
• W3006884773 hasAuthorship W3006884773A5068565363 @default.
• W3006884773 hasAuthorship W3006884773A5068950132 @default.
• W3006884773 hasAuthorship W3006884773A5070909554 @default.
• W3006884773 hasAuthorship W3006884773A5073561843 @default.
• W3006884773 hasAuthorship W3006884773A5082957036 @default.
• W3006884773 hasAuthorship W3006884773A5083708498 @default.
• W3006884773 hasAuthorship W3006884773A5089203135 @default.
• W3006884773 hasAuthorship W3006884773A5090225262 @default.
• W3006884773 hasBestOaLocation W30068847732 @default.
• W3006884773 hasConcept C126322002 @default.

• next